Natera, Inc. - Common Stock (NTRA)

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization of $47.31 billion.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

The billionaire has good reasons to like this genetic testing leader.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Duquesne Family Office has beefed up its healthcare holdings.

Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

The hedge fund legend has bet much of the family office on this one diagnostics company.

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized basis producing an average annual return of 40.99%. Currently, Natera has a market capitalization of $44.93 billion.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrow

Oncology volumes jumped 57.2% on MRD adoption gains.

Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and eme...

Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.

This sale was executed under a pre-arranged Rule 10b5-1 trading plan.

This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.

This was a non-discretionary sale to cover tax withholding on vesting equity awards under a Rule 10b5-1 plan.

Sheena executed 9,150 shares under a pre-established trading plan adopted in December 2025.

Druckenmiller only owns one "Magnificent Seven" stock.

Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $752.8...

Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women’s health and organ health businesses. The company processed approximatel

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Genetic testing company Natera (NASDAQ:NTRA) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 37.7% year on year to $752.8 mi...